Page last updated: 2024-11-07

bcx 1812

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID154234
CHEMBL ID139367
CHEBI ID85202
SCHEMBL ID12795462
SCHEMBL ID744373
MeSH IDM0370998

Synonyms (65)

Synonym
(-)-(1s,2s,3r,4r)-3-[(1s)-1-(acetylamino)-2-ethylbutyl]-4-{[amino(imino)methyl]amino}-2-hydroxycyclopentanecarboxylic acid
(1s,2s,3r,4r)-4-carbamimidamido-3-[(1s)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic acid
bdbm5024
HY-17015A
peramiflu
330600-85-6
(1s,2s,3r,4r)-3-[(1s)-1-acetamido-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentanecarboxylic acid
bcx-1812
cyclopentanecarboxylic acid, 3-[(1s)-1-(acetylamino)-2-ethylbutyl]-4-[(aminoiminomethyl)amino]-2-hydroxy-, (1s,2s,3r,4r)-
rwj-270201
bcz ,
3-(1-acetylamino-2-ethyl-butyl)-4-guanidino-2-hydroxy-cyclopentanecarboxylic acid
chebi:85202 ,
CHEMBL139367
229614-55-5
(1s,2s,3s,4r)-3-[(1s)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid
bdbm50181441
cyclopentanecarboxylic acid, 3-((1r)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1r,2r,3s,4s)-rel-
peramivir, (+/-)-
9zs94hqo3b ,
3-(1'-acetylamino-2'-ethyl)butyl-4-((aminoimino)methyl)amino-2-hydroxycyclopentane-1-carboxylic acid
bcx 1812
idl9q29886 ,
(1s,2s,3r,4r)-3-((1s)-1-acetylamino-2-ethylbutyl))-4-((aminoiminomethyl)amino)-2-hydroxycyclopentane
peramivir [usan:inn]
bcx1812
cyclopentanecarboxylic acid, 3-((1s)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1s,2s,3r,4r)-
(+/-)-peramivir
rwj270201
unii-9zs94hqo3b
rwj 270201
unii-idl9q29886
AKOS016007760
BCPP000117
CS-0638
(1s,2s,3r,4r)-3-((1s)-1-acetylamino-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxycyclopentanecarboxylic acid
peramivir [inn]
peramivir [mi]
peramivir (+/-)-form [mi]
cyclopentanecarboxylic acid, 3-((1s)-1-(acetylamino)-2-ethylbutyl)-4-((aminoiminomethyl)amino)-2-hydroxy-, (1r,2r,3s,4s)-rel-
SCHEMBL12795462
DB06614
peramivir anhydrous
SCHEMBL744373
(1s,2s,3r,4r)-3-[(1s)-1-acetamido-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentane-1-carboxylic acid
(1s,2s,3r,4r)-3-((s)-1-acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentanecarboxylic acid
(1s,2s,3r,4r)-3-((s)-1-acetamido-2-ethylbutyl)-4-guanidino-2-hydroxycyclopentane-1-carboxylic acid
AC-22715
AB01566838_01
(1s,2r,3r,4r)-3-(1-acetamido-2-ethyl-butyl)-4-(diaminomethylideneamino)-2-hydroxy-cyclopentane-1-carboxylic acid
(1s,2s,3r,4r)-3-[(1s)-1-(acetylamino)-2-ethylbutyl]-4-carbamimidamido-2-hydroxycyclopentanecarboxylic acid
DTXSID10904727
Q412734
330600-85-6 (free)
DT-0029
(1s,2s,3s,4r)-4-[(diaminomethylidene)amino]-3-[(1s)-1-acetamido-2-ethylbutyl]-2-hydroxycyclopentane-1-carboxylic acid
NCGC00346433-07
W19713
NCGC00346433-06
AKOS037652424
A896277
(1s,2s,3r,4r)-3-[(1s)-1-(acetylamino)-2-ethylbutyl]-4-[(aminoiminomethyl)amino]-2-hydroxycyclopentanecarboxylic acid trihydrate
P2892
EN300-7412041
(1s,2s,3r,4r)-3-[(1s)-1-(acetylamino)-2-ethylbutyl]-4-{[amino(imino)methyl]amino}-2-hydroxycyclopentane-1-carboxylic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No serious adverse events were reported."( Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
Kida, H; Kohno, S; Mizuguchi, M; Shimada, J, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
EC 3.2.1.18 (exo-alpha-sialidase) inhibitorAn antiviral drug targeted at influenza viruses. Its mode of action consists of blocking the function of the viral neuraminidase protein (EC 3.2.1.18), thus preventing the virus from budding from the host cell.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
cyclopentanolsAn alcohol in which one or more hydroxy groups are attached to a cyclopentane skeleton.
acetamidesCompounds with the general formula RNHC(=O)CH3.
guanidinesAny organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas.
3-hydroxy monocarboxylic acidA hydroxy monocarboxylic acid that has a hydroxy group beta to the carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuraminidase Influenza A virus (A/Turkey/651242/2006(H5N1))IC50 (µMol)0.00940.00030.31032.8247AID1403772; AID1403773
Neuraminidase Influenza A virus (A/Wilson-Smith/1933(H1N1))IC50 (µMol)0.94600.00000.503510.0000AID1308642; AID1308645; AID1308647; AID1308648; AID1308649; AID1308650; AID1308651; AID1308652; AID1403767; AID1403771; AID384920
Neuraminidase Influenza A virus (A/Brisbane/59/2007(H1N1))IC50 (µMol)0.22980.00340.14900.4510AID1403775; AID1403776; AID1403778
NeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))IC50 (µMol)0.00120.00050.976710.0000AID147346; AID147493
NeuraminidaseInfluenza A virus (A/Wilson-Smith/1933(H1N1))IC50 (µMol)0.00040.00040.13430.9930AID1403765; AID1403770
NeuraminidaseInfluenza A virus (A/Memphis/1/1971(H3N2))IC50 (µMol)0.00200.00010.00910.0324AID1403774
NeuraminidaseInfluenza B virus (B/Lee/1940)IC50 (µMol)0.00800.00100.402810.0000AID147351; AID147494
SialidaseClostridium perfringensIC50 (µMol)39.60000.00102.45729.8000AID1372135
NeuraminidaseInfluenza A virus (A/Singapore/1/1957(H2N2))IC50 (µMol)0.00300.00100.00500.0170AID1795726
Sialidase-4Homo sapiens (human)IC50 (µMol)500.00008.30008.30008.3000AID1405015; AID1889679
NeuraminidaseInfluenza A virus (A/Brevig Mission/1/1918(H1N1))IC50 (µMol)0.00340.00340.00340.0034AID636864
NeuraminidaseInfluenza A virus (A/Brevig Mission/1/1918(H1N1))Ki0.00080.00080.00080.0008AID636864
Sialidase-3Homo sapiens (human)IC50 (µMol)500.00002.40005.99808.1700AID1405014; AID1889678
Sialidase-2Homo sapiens (human)IC50 (µMol)70.00003.90006.73337.8000AID1405013
Sialidase-2Homo sapiens (human)Ki193.00005.00005.52505.7000AID1405017; AID473065
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
viral release from host cellNeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
glycoprotein catabolic processSialidase-4Homo sapiens (human)
ganglioside catabolic processSialidase-4Homo sapiens (human)
oligosaccharide catabolic processSialidase-4Homo sapiens (human)
negative regulation of neuron projection developmentSialidase-4Homo sapiens (human)
oligosaccharide catabolic processSialidase-1Homo sapiens (human)
ganglioside catabolic processSialidase-1Homo sapiens (human)
carbohydrate metabolic processSialidase-3Homo sapiens (human)
ganglioside catabolic processSialidase-3Homo sapiens (human)
oligosaccharide catabolic processSialidase-3Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwaySialidase-3Homo sapiens (human)
glycosphingolipid catabolic processSialidase-3Homo sapiens (human)
negative regulation of clathrin-dependent endocytosisSialidase-3Homo sapiens (human)
glycoprotein catabolic processSialidase-2Homo sapiens (human)
ganglioside catabolic processSialidase-2Homo sapiens (human)
oligosaccharide catabolic processSialidase-2Homo sapiens (human)
glycosphingolipid catabolic processSialidase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
exo-alpha-sialidase activityNeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
peptidase activator activityNeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
exo-alpha-sialidase activitySialidase-4Homo sapiens (human)
protein bindingSialidase-4Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-4Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-4Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-4Homo sapiens (human)
exo-alpha-sialidase activitySialidase-1Homo sapiens (human)
protein bindingSialidase-1Homo sapiens (human)
alpha-sialidase activitySialidase-1Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-1Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-1Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-1Homo sapiens (human)
exo-alpha-sialidase activitySialidase-3Homo sapiens (human)
protein bindingSialidase-3Homo sapiens (human)
alpha-sialidase activitySialidase-3Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-3Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-3Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-3Homo sapiens (human)
exo-alpha-sialidase activitySialidase-2Homo sapiens (human)
protein bindingSialidase-2Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-2Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-2Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular regionNeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
plasma membraneNeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
lysosomeSialidase-4Homo sapiens (human)
mitochondrial outer membraneSialidase-4Homo sapiens (human)
mitochondrial inner membraneSialidase-4Homo sapiens (human)
lysosomeSialidase-4Homo sapiens (human)
endoplasmic reticulum membraneSialidase-4Homo sapiens (human)
plasma membraneSialidase-4Homo sapiens (human)
organelle inner membraneSialidase-4Homo sapiens (human)
neuron projectionSialidase-4Homo sapiens (human)
lysosomal lumenSialidase-4Homo sapiens (human)
lysosomeSialidase-4Homo sapiens (human)
cytoplasmSialidase-4Homo sapiens (human)
membraneSialidase-4Homo sapiens (human)
extracellular regionSialidase-1Homo sapiens (human)
lysosomeSialidase-1Homo sapiens (human)
lysosomal membraneSialidase-1Homo sapiens (human)
plasma membraneSialidase-1Homo sapiens (human)
cell junctionSialidase-1Homo sapiens (human)
specific granule lumenSialidase-1Homo sapiens (human)
lysosomal lumenSialidase-1Homo sapiens (human)
intracellular membrane-bounded organelleSialidase-1Homo sapiens (human)
extracellular exosomeSialidase-1Homo sapiens (human)
lysosomeSialidase-1Homo sapiens (human)
cytoplasmSialidase-1Homo sapiens (human)
membraneSialidase-1Homo sapiens (human)
lysosomal membraneSialidase-3Homo sapiens (human)
plasma membraneSialidase-3Homo sapiens (human)
caveolaSialidase-3Homo sapiens (human)
external side of plasma membraneSialidase-3Homo sapiens (human)
early endosome membraneSialidase-3Homo sapiens (human)
recycling endosome membraneSialidase-3Homo sapiens (human)
membraneSialidase-3Homo sapiens (human)
lysosomeSialidase-3Homo sapiens (human)
cytoplasmSialidase-3Homo sapiens (human)
cytosolSialidase-2Homo sapiens (human)
catalytic complexSialidase-2Homo sapiens (human)
lysosomeSialidase-2Homo sapiens (human)
membraneSialidase-2Homo sapiens (human)
cytoplasmSialidase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (292)

Assay IDTitleYearJournalArticle
AID577765Toxicity in human patient infected with Influenza virus assessed as monocyte at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577733Toxicity in human patient infected with Influenza virus assessed as occurrence of nausea at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567599Antiviral activity against influenza A (A/New York/18/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID636862Antiviral activity against NP40-inactivated Influenza A virus (A/Brisbane/59/2007(H1N1)) preincubated with virus for 10 mins by viral hemagglutinination titter assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.
AID567618Antiviral activity against influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567713Ratio of IC50 for influenza A (A/Singapore/91/2009 (H1N1))virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1888150Selectivity index, ratio of CC50 for cytotoxicity against MDCK cells to EC50 for antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells2022European journal of medicinal chemistry, Jan-05, Volume: 227Discovery and optimization of new 6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline derivatives as potent influenza virus PA
AID1689108Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by MTT assay
AID565267Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID577774Toxicity in human patient infected with Influenza virus assessed as increase in alanine aminotransferase at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID1403769Cytotoxicity against MDCK cells after 48 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Peramivir conjugates as orally available agents against influenza H275Y mutant.
AID523882Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID577717Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577724Antiviral activity against Influenza virus infected in human patient assessed as resumption time of usual activities at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567727Ratio of IC50 for influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID577715Antiviral activity against Influenza virus infected in human patient assessed as reduction in fever at 300 mg, iv after 24 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID565464Cmax in healthy human at 300 mg/kg parenteral dose2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID535303Toxicity against recombinant Influenza A/WSN/33 (H1N1) virus infected BALB/c mouse assessed as weight loss at 45 mg/kg, im administered as single dose and measured after 14 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID565272Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID577737Toxicity in human patient infected with Influenza virus assessed as increase in blood glucose level at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID1372137Cytotoxicity against MDCK cells infected with Influenza A virus (A/WSN/33(H1N1)) after 72 hrs by CellTiter-Glo assay2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors.
AID515125Inhibition of Influenza B virus (B/Perth/211/2001) recombinant neuraminidase E197 mutant expressed in Sf21 insect cells preincubated for 30 mins measured after 60 mins by MUNANA based assay2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID535298Antiviral activity against oseltamivir-resistant Influenza A/WSN/33 (H1N1) virus expressing neuraminidase H274Y mutant gene infected in BALB/c mouse assessed as survival of mouse at 45 mg/kg, im administered as single dose2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID1813716Protection against Influenza A virus (A/Puerto Rico/8/34 (H1N1)) infected in Balb/c mouse at 4.2 to 8.4 uM/kg, IV administered once daily for 7 days starting from 24 hrs prior to viral infection and measured after 14 days2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.
AID577763Toxicity in human patient infected with Influenza virus assessed as nasopharyngitis at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567714Ratio of IC50 for influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID392527Antiviral activity against influenza H1N1 virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID567596Antiviral activity against influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID565475Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID565266Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID535500Antiviral activity against Influenza A/WSN/33 (H1N1) virus infected in mouse assessed as survival rate at 10 mg/kg, im administered 4 days before viral challenge2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID535307Toxicity against oseltamivir-resistant Influenza A/WSN/33 (H1N1) virus expressing neuraminidase H274Y mutant gene infected BALB/c mouse assessed as weight loss at 45 mg/kg, im once daily for 5 days measured after 14 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID567613Antiviral activity against influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID577741Plasma concentration in human at at 300 mg, iv after 18 to 24 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577742Plasma concentration in human at at 600 mg, iv after 18 to 24 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID523886Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID1403771Inhibition of Influenza A virus (A/WSN/1933(H1N1)) recombinant neuraminidase H275Y mutant expressed in HEK293 cells pre-incubated for 10 mins before 4-MUNANA substrate addition by fluorometry2018European journal of medicinal chemistry, Feb-10, Volume: 145Peramivir conjugates as orally available agents against influenza H275Y mutant.
AID567607Antiviral activity against influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID565476Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID515127Selectivity ratio of IC50 for Influenza B virus (B/Perth/211/2001) wild type recombinant neuraminidase to IC50 for Influenza B virus (B/Perth/211/2001) wild type recombinant neuraminidase preincubated for 30 mins2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID574540Toxicity in human patient infected with Influenza virus assessed as increase in blood phosphate at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID1308643Antiviral activity against oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID565270Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID515132Inhibition of Influenza B virus B/Gifu/11/2005 wild type neuraminidase expressed in Sf21 insect cells preincubated for 30 mins measured after 60 mins by MUNANA based assay2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID1689110Selectivity index, ratio of CC50 for dog MDCK cells to EC50 for Influenza A virus (A/WSN/1933(H1N1)) infected in dog MDCK cells
AID577719Antiviral activity against influenza A virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID1372135Inhibition of Clostridium perfringenes neuraminidase activity using 4-methylumbelliferyl-1-alpha-D-N-acetylneuramic acid sodium salt hydrate as substrate by fluorescence based assay2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors.
AID1403776Inhibition of Influenza A virus (A/Vietnam/1194/2004 (H5N1)) recombinant neuraminidase R292K mutant expressed in HEK293 cells pre-incubated for 10 mins before 4-MUNANA substrate addition by fluorometry2018European journal of medicinal chemistry, Feb-10, Volume: 145Peramivir conjugates as orally available agents against influenza H275Y mutant.
AID574536Toxicity in human patient infected with Influenza virus assessed as urine containing albumine at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID523883Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by NA inhibition assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID567616Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567597Antiviral activity against influenza A (A/Washington/10/2008 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID535308Toxicity against BALB/c mouse assessed as weight loss in mouse at 45 mg/kg, im once daily for 5 days measured after 14 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID567605Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1403773Inhibition of Influenza A virus (A/Vietnam/1194/2004 (H5N1)) recombinant neuraminidase H275Y mutant expressed in HEK293 cells pre-incubated for 10 mins before 4-MUNANA substrate addition by fluorometry2018European journal of medicinal chemistry, Feb-10, Volume: 145Peramivir conjugates as orally available agents against influenza H275Y mutant.
AID577760Toxicity in human patient infected with Influenza virus assessed as urine containing albumine at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID1889679Inhibition of human NEU42022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Human Neuraminidases: Structures and Stereoselective Inhibitors.
AID574541Antiviral activity against Influenza A virus H3N2 infected in human patient assessed as alleviation time of symptoms at 300 mg, iv (Rvb = 81 hrs)2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID1403774Inhibition of Influenza A virus (A/Brisbane/10/2007(H3N2)) recombinant neuraminidase expressed in HEK293 cells pre-incubated for 10 mins before 4-MUNANA substrate addition by fluorometry2018European journal of medicinal chemistry, Feb-10, Volume: 145Peramivir conjugates as orally available agents against influenza H275Y mutant.
AID535496Antiviral activity against oseltamivir-resistant Influenza A/WSN/33 (H1N1) virus expressing neuraminidase H274Y mutant gene infected in BALB/c mouse assessed as log reduction in lung viral titer at 90 mg/kg, im administered as single dose and measured aft2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID577727Antiviral activity against Influenza virus infected in human patient assessed as decrease in virus-positive patients at 300 mg, iv on day 32010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID636866Inhibition of NP40-inactivated Influenza A virus (A/Brisbane/59/2007(H1N1)) neuraminidase after 10 mins by dose responsive study2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.
AID523881Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID565274Ratio of IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID147314Fold resistance of R292K to compound against neuraminidase in a MUNANA-based enzyme inhibition assay, expressed as the ratio of IC50 of comp. with variant N9 to that of with wild-type N92002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Structural studies of the resistance of influenza virus neuramindase to inhibitors.
AID1888149Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2022European journal of medicinal chemistry, Jan-05, Volume: 227Discovery and optimization of new 6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline derivatives as potent influenza virus PA
AID224531Mean day to death of mice at 0 mg/kg/day2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
AID577752Toxicity in human patient infected with Influenza virus assessed as decrease in white blood cell count at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID384920Inhibition of influenza virus neuraminidase2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
QSAR study of neuraminidase inhibitors based on heuristic method and radial basis function network.
AID567708Ratio of IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID577773Toxicity in human patient infected with Influenza virus assessed as increase in blood bilirubin at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567608Antiviral activity against influenza A (A/Washington/10/2008 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567594Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567604Antiviral activity against influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID577764Toxicity in human patient infected with Influenza virus assessed as increase in blood phosphate at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577732Toxicity in human patient infected with Influenza virus assessed as occurrence of diarrhea at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID565469Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID565467Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1405015Inhibition of MBP-fused recombinant human neuraminidase 4 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID567722Ratio of IC50 for influenza A (A/Singapore/91/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID565273Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID565264Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID567723Ratio of IC50 for influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567710Ratio of IC50 for influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID224100Survival rate of mice infected with A/Turkey/Mass/76 XA/Beijing/32/92 (H6N2) virus at a dose of 0.1 mg/kg/day; 7/9 (7 survived out of 9 mice)2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
AID565468Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID577739Plasma concentration in human at at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID535311Antiviral activity against recombinant Influenza A/WSN/33 (H1N1) virus infected in BALB/c mouse assessed as log reduction in lung viral titer at 45 mg/kg, im once daily for 5 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID567612Antiviral activity against influenza A (A/Singapore/91/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567702Ratio of IC50 for influenza A (A/North Carolina/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme expressing wild type enzyme by NA-star substrate based chemi2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID515121Inhibition of Influenza B virus (B/Perth/211/2001) recombinant wild type neuraminidase expressed in Sf21 insect cells after 60 mins by MUNANA based assay2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID1403765Inhibition of Influenza A virus (A/WSN/1933(H1N1)) neuraminidase pre-incubated for 10 mins before 4-MUNANA substrate addition by fluorometry2018European journal of medicinal chemistry, Feb-10, Volume: 145Peramivir conjugates as orally available agents against influenza H275Y mutant.
AID1888148Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells assessed as reduction in virus induced cytopathic effect measured 48 hrs post infection by MTT assay2022European journal of medicinal chemistry, Jan-05, Volume: 227Discovery and optimization of new 6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline derivatives as potent influenza virus PA
AID1308650Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by sub2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID392531Antiviral activity against influenza virus2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID1403768Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) harboring neuraminidase H275Y mutant infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by CellTiter96 Aqueous non-radioactive cell proliferation as2018European journal of medicinal chemistry, Feb-10, Volume: 145Peramivir conjugates as orally available agents against influenza H275Y mutant.
AID535304Toxicity against recombinant Influenza A/WSN/33 (H1N1) virus infected BALB/c mouse assessed as weight loss at 90 mg/kg, im administered as single dose and measured after 14 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID567703Ratio of IC50 for influenza A (A/New York/18/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID565265Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID577756Toxicity in human patient infected with Influenza virus assessed as increase in alpha1 Microglobulin at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID515124Inhibition of Influenza B virus (B/Perth/211/2001) wild type recombinant neuraminidase expressed in Sf21 insect cells preincubated for 30 mins measured after 60 mins by MUNANA based assay2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID577747Toxicity in human patient infected with Influenza virus assessed as diarrhea at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID523885Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID147346inhibitory concentration required to inhibit neuraminidase enzyme from different strains of influenza A virus2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
AID567715Ratio of IC50 for influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID577748Toxicity in human patient infected with Influenza virus assessed as increase in lymphocyte at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID565457Ratio of IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID565479Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledo2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID515122Inhibition of Influenza B virus (B/Perth/211/2001) recombinant neuraminidase E197 mutant expressed in Sf21 insect cells after 60 mins by MUNANA based assay2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID535301Toxicity against BALB/c mouse assessed as mortality at 45 mg/kg, im once daily for 5 days measured after 14 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID636864Inhibition of Influenza A virus (A/Brevig Mission/1/1918(H1N1)) recombinant soluble neuraminidase using 2'-4(methylumbelliferyl)-alpha-D-N-acetylneuraminic acid substrate by fluorimetric assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.
AID577725Toxicity in human patient infected with Influenza virus assessed as occurrence of bronchitis at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID147493Inhibitory activity against influenza A neuraminidase2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.
AID577728Antiviral activity against Influenza virus infected in human patient assessed as decrease in virus-positive patients at 600 mg, iv on day 32010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567707Ratio of IC50 for influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID515126Fold resistance, ratio of IC50 for Influenza B virus (B/Perth/211/2001) wild type recombinant neuraminidase preincubated for 30 mins to IC50 for Influenza B virus (B/Perth/211/2001) neuraminidase E197 mutant preincubated for 30 mins2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID567588Antiviral activity against influenza A (A/New York/18/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567717Ratio of IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID565473Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1692538Oral bioavailability in ferret2020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
AID1308651Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by 2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID1308642Inhibition of oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate ad2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID577776Toxicity in human patient infected with Influenza virus assessed as increase in alpha1 microglobulin at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID1586546Inhibition of RNA-dependent RNA polymerase in Influenza A virus (A/PR/8/34(H1N1)) infected in human 293T cells assessed as reduction in viral RNA level at 10 uM measured at 3 and 6 hrs post infection by RT-PCR method2018Journal of natural products, 12-28, Volume: 81, Issue:12
Spirostaphylotrichin X from a Marine-Derived Fungus as an Anti-influenza Agent Targeting RNA Polymerase PB2.
AID535296Antiviral activity against recombinant Influenza A/WSN/33 (H1N1) virus infected in BALB/c mouse assessed as survival of mouse at 90 mg/kg, im administered as single dose2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID515138Fold resistance, ratio of Ki for Influenza B virus (B/Perth/211/2001) wild type recombinant neuraminidase preincubated for 30 mins to Ki for Influenza B virus (B/Perth/211/2001) neuraminidase E197 mutant preincubated for 30 mins2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID577759Toxicity in human patient infected with Influenza virus assessed as beta-N-Acetyl-D-glucosaminidase at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577761Toxicity in human patient infected with Influenza virus assessed as decrease in total Protein at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID574535Toxicity in human patient infected with Influenza virus assessed as beta-N-Acetyl-D-glucosaminidase at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577769Toxicity in human patient infected with Influenza virus assessed as proteinuria at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID535302Toxicity against recombinant Influenza A/WSN/33 (H1N1) virus infected BALB/c mouse assessed as weight loss at 45 mg/kg, im once daily for 5 days measured after 14 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID1889678Inhibition of human NEU32022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Human Neuraminidases: Structures and Stereoselective Inhibitors.
AID567617Antiviral activity against influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID577726Toxicity in human patient infected with Influenza virus assessed as occurrence of otitis at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567606Antiviral activity against influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1405019Inhibition of MBP-fused recombinant human neuraminidase 4 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID515134Fold resistance, ratio of IC50 for Influenza B virus B/Gifu/11/2005 wild type neuraminidase preincubated for 30 mins to IC50 for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant preincubated for 30 mins2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID515130Inhibition of Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant expressed in Sf21 insect cells after 60 mins by MUNANA based assay2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID523884Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by fluorescent NA inhibition assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID523880Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by NA inhibition assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID577730Antiviral activity against Influenza virus infected in human patient assessed as decrease in virus-positive patients at 600 mg, iv on day 92010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567595Antiviral activity against influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1403772Inhibition of Influenza A virus (A/Vietnam/1194/2004 (H5N1)) recombinant neuraminidase expressed in HEK293 cells pre-incubated for 10 mins before 4-MUNANA substrate addition by fluorometry2018European journal of medicinal chemistry, Feb-10, Volume: 145Peramivir conjugates as orally available agents against influenza H275Y mutant.
AID515140Fold resistance, ratio of Ki for Influenza B virus B/Gifu/11/2005 wild type neuraminidase preincubated for 30 mins to Ki for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant preincubated for 30 mins2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID636865Inhibition of Influenza A virus (A/Brevig Mission/1/1918(H1N1)) recombinant neuraminidase by dose responsive study2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.
AID515123Fold resistance, ratio of IC50 for Influenza B virus (B/Perth/211/2001) recombinant wild type neuraminidase to IC50 for Influenza B virus (B/Perth/211/2001) recombinant neuraminidase E197 mutant2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID535297Antiviral activity against recombinant Influenza A/WSN/33 (H1N1) virus infected in BALB/c mouse assessed as survival of mouse at 45 mg/kg, im once daily for 5 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID577744Plasma concentration in human at at 600 mg, iv after 36 to 48 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID224099Survival rate of mice infected with A/Turkey/Mass/76 XA/Beijing/32/92 (H6N2) virus at a dose of 0 mg/kg/day; 1/9 (1 survived out of 9 mice)2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
AID567704Ratio of IC50 for influenza A (A/Singapore/91/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID565478Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/122009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID565269Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID567592Antiviral activity against influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID567725Ratio of IC50 for influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID636871Competitive inhibition of Influenza A virus (A/Brevig Mission/1/1918(H1N1)) recombinant soluble neuraminidase at at 0.7 to 3 nM using 2'-4(methylumbelliferyl)-alpha-D-N-acetylneuraminic acid substrate by fluorimetric based Michaelis-Menten equation analys2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.
AID565461Ratio of IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID567602Antiviral activity against influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID577740Plasma concentration in human at at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577736Toxicity in human patient infected with Influenza virus assessed as prolongation of electrocardiogram QT interval at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567587Antiviral activity against influenza A (A/North Carolina/02/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID515131Fold resistance, ratio of IC50 for Influenza B virus B/Gifu/11/2005 wild type neuraminidase to IC50 for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID567705Ratio of IC50 for influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID535300Antiviral activity against oseltamivir-resistant Influenza A/WSN/33 (H1N1) virus expressing neuraminidase H274Y mutant gene infected in BALB/c mouse assessed as survival of mouse at 45 mg/kg, im once daily for 5 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID565470Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID577762Toxicity in human patient infected with Influenza virus assessed as lymphocyte morphology abnormal at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID1403775Inhibition of Influenza A virus (A/Vietnam/1194/2004 (H5N1)) recombinant neuraminidase E119A mutant expressed in HEK293 cells pre-incubated for 10 mins before 4-MUNANA substrate addition by fluorometry2018European journal of medicinal chemistry, Feb-10, Volume: 145Peramivir conjugates as orally available agents against influenza H275Y mutant.
AID565471Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID577778Toxicity in human patient infected with Influenza virus assessed as increase in blood lactate dehydrogenase at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID574539Toxicity in human patient infected with Influenza virus assessed as nasopharyngitis at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567711Ratio of IC50 for influenza A (A/North Carolina/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1857995Inhibition of influenza virus neuraminidase2022Journal of medicinal chemistry, 10-27, Volume: 65, Issue:20
Sialidase Inhibitors with Different Mechanisms.
AID473065Inhibition of human neuraminidase 22010Journal of medicinal chemistry, Apr-08, Volume: 53, Issue:7
Complexity in influenza virus targeted drug design: interaction with human sialidases.
AID567586Antiviral activity against influenza A (A/Washington/10/2008 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID577721Antiviral activity against Influenza A virus H1N1 infected in human patient assessed as alleviation time of symptoms at 300 mg, iv (Rvb = 81.4 hrs)2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577743Plasma concentration in human at at 300 mg, iv after 36 to 48 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID535495Antiviral activity against oseltamivir-resistant Influenza A/WSN/33 (H1N1) virus expressing neuraminidase H274Y mutant gene infected in BALB/c mouse assessed as log reduction in lung viral titer at 45 mg/kg, im administered as single dose and measured aft2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID535310Antiviral activity against recombinant Influenza A/WSN/33 (H1N1) virus infected in BALB/c mouse assessed as log reduction in lung viral titer at 90 mg/kg, im administered as single dose and measured after 4 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID535501Antiviral activity against Influenza A/WSN/33 (H1N1) virus infected in mouse assessed as survival rate at 10 mg/kg, po administered 4 days before viral challenge2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID577729Antiviral activity against Influenza virus infected in human patient assessed as decrease in virus-positive patients at 300 mg, iv on day 92010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID1405013Inhibition of MBP-fused recombinant human neuraminidase 2 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID574538Toxicity in human patient infected with Influenza virus assessed as lymphocyte morphology abnormal at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577755Toxicity in human patient infected with Influenza virus assessed as increase in aspartate aminotransferase at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567726Ratio of IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID515137Fold resistance, ratio of Ki for Influenza B virus (B/Perth/211/2001) recombinant wild type neuraminidase to Ki for Influenza B virus (B/Perth/211/2001) recombinant neuraminidase E197 mutant2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID535305Toxicity against oseltamivir-resistant Influenza A/WSN/33 (H1N1) virus expressing neuraminidase H274Y mutant gene infected BALB/c mouse assessed as weight loss at 45 mg/kg, im administered as single dose and measured after 6 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID515128Selectivity ratio of IC50 for Influenza B virus (B/Perth/211/2001) recombinant neuraminidase E197 mutant to IC50 for Influenza B virus (B/Perth/211/2001) neuraminidase E197 mutant preincubated for 30 mins2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID1308649Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase R292K mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID523887Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by fluorescent NA inhibition assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID567709Ratio of IC50 for influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID565477Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID577746Toxicity in human patient infected with Influenza virus assessed as increase in blood glucose at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577749Toxicity in human patient infected with Influenza virus assessed as proteinuria at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID636867Competitive inhibition of Influenza A virus (A/Brevig Mission/1/1918(H1N1)) recombinant soluble neuraminidase at 0.7 to 3 nM using 2'-4(methylumbelliferyl)-alpha-D-N-acetylneuraminic acid substrate by fluorimetric based Lineweaver-Burk plot analysis2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.
AID224101Survival rate of mice infected with A/Turkey/Mass/76 XA/Beijing/32/92 (H6N2) virus at a dose of 1.0 mg/kg/day; 9/9 (9 survived out of 9 mice)2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
AID567590Antiviral activity against influenza A (A/Singapore/91/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID515129Inhibition of Influenza B virus B/Gifu/11/2005 wild type neuraminidase expressed in Sf21 insect cells after 60 mins by MUNANA based assay2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID567718Ratio of IC50 for influenza A (A/Hong Kong/2369/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID577735Toxicity in human patient infected with Influenza virus assessed as prolongation of electrocardiogram QT interval at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID1308645Inhibition of Influenza A virus A/WSN/1933(H1N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured aft2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID567609Antiviral activity against influenza A (A/North Carolina/02/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID636863Antiviral activity against NP40-inactivated Influenza A virus (A/Brisbane/59/2007(H1N1)) preincubated with virus for 2 hrs by viral hemagglutinination titter assay2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
The de-guanidinylated derivative of peramivir remains a potent inhibitor of influenza neuraminidase.
AID577722Antiviral activity against Influenza A virus H1N1 infected in human patient assessed as alleviation time of symptoms at 600 mg, iv (Rvb = 81.4 hrs)2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID535502Cmax in mouse at 30 mg/kg, im administered as single dose and measured after 30 mins2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID567603Antiviral activity against influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1405014Inhibition of MBP-fused recombinant human neuraminidase 3 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID577750Toxicity in human patient infected with Influenza virus assessed as white blood cells-positive urine at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567614Antiviral activity against influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID515135Selectivity ratio of IC50 for Influenza B virus B/Gifu/11/2005 wild type neuraminidase to IC50 for Influenza B virus B/Gifu/11/2005 wild type neuraminidase preincubated for 30 mins2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID147312Fold resistance of E119G to compound against neuraminidase in a MUNANA-based enzyme inhibition assay, expressed as the ratio of IC50 of comp. with variant N9 to that of with wild-type N92002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Structural studies of the resistance of influenza virus neuramindase to inhibitors.
AID535499Binding affinity to Influenza A/WSN/33 (H1N1) neuraminidase infected in mouse assessed as half-time for substrate conversion at 2 to 20 mg/kg/day, po administered as single dose2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID567719Ratio of IC50 for influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID535306Toxicity against oseltamivir-resistant Influenza A/WSN/33 (H1N1) virus expressing neuraminidase H274Y mutant gene infected BALB/c mouse assessed as weight loss at 90 mg/kg, im administered as single dose and measured after 14 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID565462Ratio of IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID515139Fold resistance, ratio of Ki for Influenza B virus B/Gifu/11/2005 wild type neuraminidase to Ki for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID565474Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID577775Toxicity in human patient infected with Influenza virus assessed as increase in aspartate aminotransferase at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567720Ratio of IC50 for influenza A (A/North Carolina/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1308648Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase E119A mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID535295Antiviral activity against recombinant Influenza A/WSN/33 (H1N1) virus infected in BALB/c mouse assessed as survival of mouse at 45 mg/kg, im administered as single dose2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID535503Cmax in mouse at 30 mg/kg, im administered as single dose and measured after 24 hrs2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID577777Toxicity in human patient infected with Influenza virus assessed as nausea at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID515136Selectivity ratio of IC50 for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant to IC50 for Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant preincubated for 30 mins2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID147494Inhibitory activity against influenza B neuraminidase2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.
AID577720Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID1405017Inhibition of MBP-fused recombinant human neuraminidase 2 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID574542Antiviral activity against Influenza A virus H3N2 infected in human patient assessed as alleviation time of symptoms at 600 mg, iv (Rvb = 81 hrs)2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID535309Antiviral activity against recombinant Influenza A/WSN/33 (H1N1) virus infected in BALB/c mouse assessed as log reduction in lung viral titer at 45 mg/kg, im administered as single dose and measured after 4 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID567716Ratio of IC50 for influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1372136Antiviral activity against Influenza A virus (A/WSN/33(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors.
AID515133Inhibition of Influenza B virus B/Yamagata/186/05 neuraminidase N197 mutant expressed in Sf21 insect cells preincubated for 30 mins measured after 60 mins by MUNANA based assay2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.
AID567712Ratio of IC50 for influenza A (A/New York/18/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID577718Antiviral activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577751Toxicity in human patient infected with Influenza virus assessed as beta2 microglobulin in urine at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567591Antiviral activity against influenza A (A/North Carolina/01/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID577745Toxicity in human patient infected with Influenza virus assessed as increase in monocyte at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID565458Ratio of IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID567611Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID565459Ratio of IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1308644Cytotoxicity against MDCK cells after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID567598Antiviral activity against influenza A (A/North Carolina/02/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID577716Antiviral activity against Influenza virus infected in human patient assessed as reduction in fever at 600 mg, iv after 24 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID574537Toxicity in human patient infected with Influenza virus assessed as decrease in total Protein at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID1405016Inhibition of recombinant His6-tagged human neuraminidase 1 expressed in HEK293 cells using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID535498Binding affinity to Influenza A/WSN/33 (H1N1) neuraminidase infected in mouse assessed as half-time for substrate conversion at 10 mg/kg, im administered as single dose2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID1403767Inhibition of Influenza A virus (A/WSN/1933(H1N1)) neuraminidase H275Y mutant pre-incubated for 10 mins before 4-MUNANA substrate addition by fluorometry2018European journal of medicinal chemistry, Feb-10, Volume: 145Peramivir conjugates as orally available agents against influenza H275Y mutant.
AID577731Toxicity in human patient infected with Influenza virus assessed as occurrence of diarrhea at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567615Antiviral activity against influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID565472Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID577723Antiviral activity against Influenza virus infected in human patient assessed as resumption time of usual activities at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577757Toxicity in human patient infected with Influenza virus assessed as nausea at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577738Toxicity in human patient infected with Influenza virus assessed as increase in blood creatinine level at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577766Toxicity in human patient infected with Influenza virus assessed as increase in blood glucose at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567724Ratio of IC50 for influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID535497Antiviral activity against oseltamivir-resistant Influenza A/WSN/33 (H1N1) virus expressing neuraminidase H274Y mutant gene infected in BALB/c mouse assessed as log reduction in lung viral titer at 45 mg/kg, im once daily for 5 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID577770Toxicity in human patient infected with Influenza virus assessed as white blood cells-positive urine at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567601Antiviral activity against influenza A (A/Singapore/91/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID577754Toxicity in human patient infected with Influenza virus assessed as increase in alanine aminotransferase at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567610Antiviral activity against influenza A (A/New York/18/2009 (H1N1)) virus after 16 to 18 hrs by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID565271Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID1889676Inhibition of human NEU12022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Human Neuraminidases: Structures and Stereoselective Inhibitors.
AID147351inhibitory concentration required to inhibit neuraminidase enzyme from different strains of influenza B virus.2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
AID224532Mean day to death of mice at 0.1 mg/kg/day2000Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19
BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
AID567721Ratio of IC50 for influenza A (A/New York/18/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/10/2008 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1405018Inhibition of MBP-fused recombinant human neuraminidase 3 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID1308647Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID567728Ratio of IC50 for influenza A (A/Singapore/57/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by fetuin substrate based colorimetric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1403778Inhibition of Influenza A virus (A/Shanghai/01/2014(H7N9)) recombinant neuraminidase R292K mutant expressed in HEK293 cells pre-incubated for 10 mins before 4-MUNANA substrate addition by fluorometry2018European journal of medicinal chemistry, Feb-10, Volume: 145Peramivir conjugates as orally available agents against influenza H275Y mutant.
AID1403766Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Peramivir conjugates as orally available agents against influenza H275Y mutant.
AID565268Ratio of IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant to IC50 for Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID577772Toxicity in human patient infected with Influenza virus assessed as decrease in white blood cell count at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567593Antiviral activity against influenza A (A/Osaka/180/2009 (H1N1)) virus harboring neuraminidase H275Y mutant after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID565275Ratio of IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant to IC50 for Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID577767Toxicity in human patient infected with Influenza virus assessed as diarrhea at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567706Ratio of IC50 for influenza A (A/Montana/02/2009 (H1N1)) virus harboring neuraminidase H275Y mutant to IC50 for influenza A (A/Washington/29/2009 (H1N1)) virus expressing wild type enzyme by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID565460Ratio of IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant to IC50 for Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.
AID523879Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD2 additional passages in MDCK cells by NA inhibition assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance.
AID577771Toxicity in human patient infected with Influenza virus assessed as beta2 microglobulin in urine at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577768Toxicity in human patient infected with Influenza virus assessed as increase in lymphocyte at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567589Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus after 30 mins by NA-star substrate based chemiluminescent assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1689109Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID1308652Inhibition of Influenza A virus A/Shanghai/01/2014(H7N9) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
AID577734Toxicity in human patient infected with Influenza virus assessed as occurrence of nausea at 600 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID577753Toxicity in human patient infected with Influenza virus assessed as increase in blood bilirubin at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID567600Antiviral activity against influenza A (A/Washington/29/2009 (H1N1)) virus after 30 mins by MUNANA substrate based fluorometric assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
AID1403770Inhibition of Influenza A virus (A/WSN/1933(H1N1)) recombinant neuraminidase expressed in HEK293 cells pre-incubated for 10 mins before 4-MUNANA substrate addition by fluorometry2018European journal of medicinal chemistry, Feb-10, Volume: 145Peramivir conjugates as orally available agents against influenza H275Y mutant.
AID535299Antiviral activity against oseltamivir-resistant Influenza A/WSN/33 (H1N1) virus expressing neuraminidase H274Y mutant gene infected in BALB/c mouse assessed as survival of mouse at 90 mg/kg, im administered as single dose2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.
AID1405012Inhibition of recombinant His6-tagged human neuraminidase 1 expressed in HEK293 cells using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID577758Toxicity in human patient infected with Influenza virus assessed as increase in blood lactate dehydrogenase at 300 mg, iv2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
AID1403777Inhibition of Influenza A virus (A/Shanghai/01/2014(H7N9)) recombinant neuraminidase expressed in HEK293 cells pre-incubated for 10 mins before 4-MUNANA substrate addition by fluorometry2018European journal of medicinal chemistry, Feb-10, Volume: 145Peramivir conjugates as orally available agents against influenza H275Y mutant.
AID1795726Neuraminidase Inhibition Assay from Article 10.1021/jm010277p: \\Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.\\2001Journal of medicinal chemistry, Dec-06, Volume: 44, Issue:25
Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (24.00)29.6817
2010's12 (48.00)24.3611
2020's7 (28.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.44 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index5.55 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.00%)5.53%
Reviews2 (8.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (88.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]